fusidic acid has been researched along with posaconazole in 2 studies
| Studies (fusidic acid) | Trials (fusidic acid) | Recent Studies (post-2010) (fusidic acid) | Studies (posaconazole) | Trials (posaconazole) | Recent Studies (post-2010) (posaconazole) |
|---|---|---|---|---|---|
| 1,742 | 117 | 344 | 1,575 | 103 | 1,014 |
| Protein | Taxonomy | fusidic acid (IC50) | posaconazole (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 8.1 | |
| Steroid 17-alpha-hydroxylase/17,20 lyase | Homo sapiens (human) | 0.921 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.2458 | |
| Aromatase | Homo sapiens (human) | 8.4 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 7.2 | |
| Cytochrome P450 11B1, mitochondrial | Homo sapiens (human) | 0.31 | |
| Cytochrome P450 11B2, mitochondrial | Homo sapiens (human) | 0.021 | |
| Sterol 14-alpha demethylase | Trypanosoma cruzi strain CL Brener | 0.464 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 6 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
1 review(s) available for fusidic acid and posaconazole
| Article | Year |
|---|---|
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
1 other study(ies) available for fusidic acid and posaconazole
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |